Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer
Purpose: There is substantial germline genetic variability within angiogenesis pathway
genes, thereby causing interindividual differences in angiogenic capacity and resistance to …
genes, thereby causing interindividual differences in angiogenic capacity and resistance to …
VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Bevacizumab is used to treat metastatic colorectal cancer (mCRC). However, there are still
no available predictors of clinical outcomes. We investigated selected single nucleotide …
no available predictors of clinical outcomes. We investigated selected single nucleotide …
Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined …
BS Sohn, SJ Park, JE Kim, K Kim, YS Hong, C Suh… - Oncology, 2014 - karger.com
Objective: The aim of this study was to evaluate the association between the efficacy of first-
line cytotoxic chemotherapy plus bevacizumab and single-nucleotide polymorphisms …
line cytotoxic chemotherapy plus bevacizumab and single-nucleotide polymorphisms …
[HTML][HTML] IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
Background Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been
validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in …
validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in …
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with …
TF Hansen, RP Christensen, RF Andersen… - International journal of …, 2012 - Springer
Purpose Bevacizumab and chemotherapy is a common choice for first-line treatment of
metastatic colorectal cancer (mCRC). So far, no predictive markers have been identified …
metastatic colorectal cancer (mCRC). So far, no predictive markers have been identified …
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
Background: The identification of molecular and genetic markers to predict or monitor the
efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal …
efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal …
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and …
V Formica, R Palmirotta, G Del Monte… - International journal of …, 2011 - Springer
Purpose The aim of this study is to evaluate the influence of germline vascular endothelial
growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the anti-VEGF antibody …
growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the anti-VEGF antibody …
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the …
G Pentheroudakis, V Kotoula, E Fountzilas… - BMC cancer, 2014 - Springer
Background Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor
(VEGF), is licensed for the management of patients with advanced colon cancer. However …
(VEGF), is licensed for the management of patients with advanced colon cancer. However …
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
Background Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
P Ulivi, E Scarpi, A Passardi, G Marisi, D Calistri… - Journal of translational …, 2015 - Springer
Background Bevacizumab plus chemotherapy is a widely used therapeutic option for first-
line treatment of metastatic colorectal cancer (mCRC). However, molecular predictors of …
line treatment of metastatic colorectal cancer (mCRC). However, molecular predictors of …